Fast-forward to 2026, and we’ve already seen a handful of U.S. biotechs line up to squeeze through a gradually reopening IPO ...

A federal grand jury in Rhode Island has charged two former top executives of Colorado-based medical device company Zynex Inc. | A federal grand jury in Rhode Island has charged two former top ...

As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...

In a reminder of the money still on the table for enticing obesity assets, Corxel Pharmaceuticals has raised $287 million in ...

T-cell engagers are antibody-based therapeutics that can reprogram T cells for antigen-specific elimination of target cells. The modality has remained a big draw for Big Pharma, with Eli Lilly penning ...

That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...

Genomics and life sciences pioneer J. Craig Venter, Ph.D., is back with a new J. | Genomics and life sciences pioneer J.

Corcept Therapeutics’ relacorilant has improved overall survival (OS) in a phase 3 ovarian cancer study, building on interim data published last year and giving the biotech momentum as it heads into ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Hoth Therapeutics has shared phase 2 results on its treatment of EGFR inhibitor-induced skin toxicities, ticking off another ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...